Chemotherapy-Induced Peripheral Neurotoxicity as A Risk Factor for Poor Sleep Quality in Breast Cancer Survivors Treated with Docetaxel

Abstract Recent evidence has shown that poor quality sleep is associated with depression, particularly among older individuals (Bao et al., 2017; Nadorff, Fiske, Sperry, & Petts, 2012). Moreover, given the high prevalence of depressive symptoms among older adults, it is important to identify possible risk factors of poor sleep quality. One possible risk factor is being a custodial grandparent (raising one’s grandchildren), as increased caregiving responsivities are associated with increased depressive symptoms (Brand-Winterstein, Edelstein, & Bachner, 2018). Based upon these previous findings, the current study examines the effect of custodial status on the relation between sleep quality and depressive symptoms. The sample (N = 466) was a subset of individuals recruited in the second wave of the MIDUS biomarkers project completed in 2009 who answered the sleep, caregiving, and depressive symptoms variables of interest. Measures included the Center for Epidemiological Studies Depression Scale (CESD), the Pittsburgh Sleep Quality Index (PSQI), and a question regarding custodial grandparent status. The current study aimed to examine whether poor sleep quality might serve as a risk factor for experiencing depressive symptoms and how custodial grandparents might differ from other older adults. Moderation analyses were conducted using SPSS’ Process macro on the sample. The interaction between global sleep quality and custodial grandparent status was significant in predicting depressive symptoms, t (1, 465) = 3.90, p = .04, such that custodial grandparents reported a stronger positive correlation between greater global sleep problems and depressive symptoms than non-custodial grandparents. Implications, future directions, and limitations are discussed.

Download Full-text

3367 A Mouse Model of APOE Genotype in Chemotherapy Related Cognitive Impairment

Journal of Clinical and Translational Science ◽

10.1017/cts.2019.6 ◽

2019 ◽

Vol 3 (s1) ◽

pp. 1-1

Author(s):

Tamar Demby ◽

G. William Rebeck ◽

Christopher Albanese ◽

Olga C. Rodriguez ◽

Yichien Lee ◽

...

Keyword(s):

Breast Cancer ◽

Risk Factor ◽

Cognitive Impairment ◽

Cancer Survivors ◽

Open Field ◽

Breast Cancer Survivors ◽

Apoe Genotype ◽

Post Treatment ◽

Barnes Maze ◽

Doxorubicin Treatment

OBJECTIVES/SPECIFIC AIMS: Chemotherapy-related cognitive impairment (CRCI) affects 15-35% of breast cancer survivors and constitutes a significant challenge for survivor quality of life. Among older breast cancer survivors who received chemotherapy treatment, carriers of at least one ɛ4 allele of the APOE gene, which encodes apolipoprotein E, are at higher risk for developing CRCI than non-carriers. APOE4 is well characterized as the strongest genetic risk factor for Alzheimer’s disease, but how it contributes to CRCI is not yet understood, and no animal models of APOE genotype and CRCI have yet been established. To better understand how APOE4 acts as a risk factor for CRCI, we used APOE targeted replacement (TR) mice to develop a model of its effects on cognition following treatment with doxorubicin, a chemotherapy drug commonly used in breast cancer treatment. METHODS/STUDY POPULATION: Twelve-to-thirteen month old APOE3 and APOE4 targeted replacement mice expressing human APOE3 or human APOE4 under control of the endogenous murine promoter were treated with 10 mg/kg doxorubicin or equivolume saline given via two IP injections spaced one week apart. One week post-treatment, mice were tested using Open Field and Elevated Zero apparatuses to assess baseline locomotive activity and anxiety and exploratory behaviors. Five weeks post-treatment, mice were assessed using the Barnes Maze over four days of training trials and one 72 hour memory probe. RESULTS/ANTICIPATED RESULTS: We found no differences in Open Field and Elevated Zero behavior, indicating limited influence of doxorubicin treatment on locomotive and anxiety behaviors in both genotypes. During Barnes Maze training, APOE4 mice treated with doxorubicin showed increased latency compared to untreated APOE4 mice as well as treated and untreated APOE3 mice, indicating deficiencies in spatial learning. In APOE3 mice, no differences in performance were seen between doxorubicin-treated and untreated mice (n = 15-16/group, p <.0001). DISCUSSION/SIGNIFICANCE OF IMPACT: These results indicate that APOE4 targeted replacement mice have specific cognitive vulnerabilities to doxorubicin treatment that can be reliably detected using the Barnes Maze assessment. Future directions include experiments to determine how other chemotherapy drugs or drug combinations impact cognition of APOE4 mice. Ultimately this model may be used to assess preventive measures or therapies for CRCI in the vulnerable APOE4 carrier population with the ability to validate cognitive impacts of these interventions.

Download Full-text

Poor Sleep Quality As a Risk Factor for Poorly-Controlled Asthma in Children

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2014.12.1509 ◽

2015 ◽

Vol 135 (2) ◽

pp. AB176

Author(s):

Youn Ho Shin ◽

Sun Jung Jang ◽

Ji Hyeon Baek ◽

Hye Mi Jee ◽

Kyu Young Chae ◽

...

Keyword(s):

Risk Factor ◽

Sleep Quality ◽

Poor Sleep ◽

Poor Sleep Quality ◽

Asthma In Children

Download Full-text

Inflammation and psychosocial factors mediate exercise effects on sleep quality in breast cancer survivors: pilot randomized controlled trial

Psycho-Oncology ◽

10.1002/pon.3594 ◽

2014 ◽

Vol 24 (3) ◽

pp. 302-310 ◽

Cited By ~ 27

Author(s):

Laura Q. Rogers ◽

Amanda Fogleman ◽

Rita Trammell ◽

Patricia Hopkins-Price ◽

Allison Spenner ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Controlled Trial ◽

Sleep Quality ◽

Cancer Survivors ◽

Psychosocial Factors ◽

Breast Cancer Survivors ◽

Controlled Trial ◽

Randomized Controlled ◽

Pilot Randomized Controlled Trial

Download Full-text

Efficacy of ear acupuncture on sleep quality in breast cancer survivors: A randomized controlled trial.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.12066 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. 12066-12066

Author(s):

Melanie Désirée Hoextermann ◽

Katja Buner ◽

Heidemarie Haller ◽

Wiebke Kohl ◽

Mattea Reinisch ◽

...

Keyword(s):

Breast Cancer ◽

Randomized Controlled Trial ◽

Sleep Quality ◽

Cancer Survivors ◽

Breast Cancer Survivors ◽

Sleep Problems ◽

Controlled Trial ◽

Ear Acupuncture ◽

Significant Group ◽

Randomized Controlled

12066 Background: Among females, breast cancer is the most commonly diagnosed cancer worldwide. Sleep problems impair 40 to 70 % of breast cancer survivors. The aim of this randomized controlled trial was to evaluate the effect of ear acupuncture on sleep quality in breast cancer survivors. Methods: Fifty-two female breast cancer survivors (mean age 55.73 ± 8.10) were randomized to either 10 treatments of ear acupuncture within five weeks (N = 26) or to a single session of psycho-education and given an advice booklet concerning insomnia (N = 26). Both interventions were delivered in a group setting. Primary outcome was sleep quality (measured by the Pittsburgh Sleep Quality Index) at week 5 corrected for treatment expectancies. Secondary outcomes were inflammation parameters (interleukin-6) at week 5, sleep quality at week 17, and stress, anxiety, depressive symptoms, quality of life and fatigue 5 weeks and 17 weeks after randomization. Results: Intention-to-treat analysis showed a significantly stronger increase of sleep quality in the ear acupuncture group compared to the psycho-education group ( p= .031; d = 0.64) at week 5. Furthermore, ear acupuncture improved stress ( p= .030; d = 0.64), anxiety ( p = .001; d = 0.97), and fatigue ( p = .012; d = 0.75) at week 5 compared to psycho-education. No significant group difference was found on any outcome at week 17. No serious adverse events occurred during the study period. Conclusions: Group ear acupuncture may be a helpful intervention in tackling sleep problems in breast cancer survivors in the short term and may reduce stress, anxiety and fatigue as well. Long-term effects remain questionable. Clinical trial information: NCT03874598 .

Download Full-text